Carfilzomib is a second-generation tetrapeptide epoxyketone proteasome inhibitor^1,2

• Binds irreversibly to the 20S proteasome, the proteolytic core particle within the 26S proteasome¹
• Antiproliferative and pro-apoptotic activities in preclinical models¹
• Minimal inhibition against a panel of 21 non-proteasomal proteases in vitro¹

Adapted from Murata et al³ and Ruschak et al.⁴

* Clinical significance has not been established.